CoChat
Sign Up
Cited by 592

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts

Valent, Peter, Akin, Cem, Metcalfe, Dean D.·2017·Blood
DOI 10.1182/blood-2016-09-731893
Open this paper in CoChat — free account

Abstract

Over the past few years, substantial advances have been made in understanding the pathogenesis, evolution, and complexity of mast cell neoplasms. New diagnostic and prognostic parameters and novel therapeutic targets with demonstrable clinical impact have been identified. Several of these new markers, molecular targets, and therapeutic approaches have been validated and translated into clinical practice. At the same time, the classification of mastocytosis and related diagnostic criteria have been refined and updated by the consensus group and the World Health Organization (WHO). As a result, more specific therapies tailored toward prognostic subgroups of patients have been developed. Emerging treatment concepts use drugs directed against KIT and other relevant targets in neoplastic mast cells and will hopefully receive recognition by health authorities in the near future. This article provides an overview of recent developments in the field, with emphasis on the updated WHO classification, refined criteria, additional prognostic parameters, and novel therapeutic approaches. Based on these emerging concepts, the prognosis, quality of life, and survival of patients with advanced mastocytosis are expected to improve in the coming years.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2016-09-731893

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 95

  1. Parwaresch, 1985, Tissue mast cells in health and disease, Pathol Res Pract, 179, 439, 10.1016/S0344-0338(85)80184-9 · DOI
  2. Valent, 2003, Diagnosis and treatment of systemic mastocytosis: state of the art, Br J Haematol, 122, 695, 10.1046/j.1365-2141.2003.04575.x · DOI
  3. Metcalfe, 2008, Mast cells and mastocytosis, Blood, 112, 946, 10.1182/blood-2007-11-078097 · DOI · Paper page
  4. Horny, 1985, Bone marrow findings in systemic mastocytosis, Hum Pathol, 16, 808, 10.1016/S0046-8177(85)80252-5 · DOI
  5. Horny, 2001, Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings, Leuk Res, 25, 543, 10.1016/S0145-2126(01)00021-2 · DOI
  6. Metcalfe, 1991, Classification and diagnosis of mastocytosis: current status, J Invest Dermatol, 96, 2S, 10.1111/1523-1747.ep12468882 · DOI
  7. Valent, 1996, Biology, classification and treatment of human mastocytosis, Wien Klin Wochenschr, 108, 385
  8. Valent, 2001, Diagnostic criteria and classification of mastocytosis: a consensus proposal, Leuk Res, 25, 603, 10.1016/S0145-2126(01)00038-8 · DOI
  9. Nettleship, 1869, Rare forms of urticaria, Br Med J, 2, 323
  10. Ellis, 1949, Urticaria pigmentosa; a report of a case with autopsy, Arch Pathol (Chic), 48, 426
  11. Caplan, 1963, The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases, Arch Dermatol, 87, 146, 10.1001/archderm.1963.01590140008002 · DOI
  12. Escribano, 2002, Mastocytosis: current concepts in diagnosis and treatment, Ann Hematol, 81, 677, 10.1007/s00277-002-0575-z · DOI
  13. Arock, 2010, Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives, Expert Rev Hematol, 3, 497, 10.1586/ehm.10.42 · DOI
  14. Nagata, 1995, Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder, Proc Natl Acad Sci USA, 92, 10560, 10.1073/pnas.92.23.10560 · DOI
  15. Longley, 1996, Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm, Nat Genet, 12, 312, 10.1038/ng0396-312 · DOI
  16. Fritsche-Polanz, 2001, Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis, Br J Haematol, 113, 357, 10.1046/j.1365-2141.2001.02783.x · DOI
  17. Horny, 1998, Diagnostic value of immunostaining for tryptase in patients with mastocytosis, Am J Surg Pathol, 22, 1132, 10.1097/00000478-199809000-00013 · DOI
  18. Escribano, 1998, Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications, Blood, 91, 2731, 10.1182/blood.V91.8.2731.2731_2731_2736 · DOI
  19. Schwartz, 2000, Serum tryptase and the laboratory diagnosis of systemic mastocytosis, Hematol Oncol Clin North Am, 14, 641, 10.1016/S0889-8588(05)70300-2 · DOI
  20. Sperr, 2001, Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis, Leuk Res, 25, 529, 10.1016/S0145-2126(01)00041-8 · DOI
  21. Valent, 1999, Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998, Int Arch Allergy Immunol, 120, 1, 10.1159/000024214 · DOI
  22. Hartmann, 2016, Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology, J Allergy Clin Immunol, 137, 35, 10.1016/j.jaci.2015.08.034 · DOI
  23. Valent, 2014, Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal, Ann Oncol, 25, 1691, 10.1093/annonc/mdu047 · DOI
  24. Lim, 2009, Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors, Blood, 113, 5727, 10.1182/blood-2009-02-205237 · DOI
  25. Escribano, 2009, Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients, J Allergy Clin Immunol, 124, 514, 10.1016/j.jaci.2009.05.003 · DOI
  26. Pardanani, 2009, Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies, Blood, 114, 3769, 10.1182/blood-2009-05-220145 · DOI
  27. Pardanani, 2010, WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults, Blood, 115, 150, 10.1182/blood-2009-10-249979 · DOI
  28. Travis, 1986, Mast cell leukemia: report of a case and review of the literature, Mayo Clin Proc, 61, 957, 10.1016/S0025-6196(12)62636-6 · DOI
  29. Valent, 2015, Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features, Leuk Res, 39, 1, 10.1016/j.leukres.2014.09.010 · DOI
  30. Arock, 2015, KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis, Leukemia, 29, 1223, 10.1038/leu.2015.24 · DOI · Paper page
  31. Mayerhofer, 2008, Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens, J Immunol, 180, 5466, 10.4049/jimmunol.180.8.5466 · DOI
  32. Zappulla, 2005, Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation, J Exp Med, 202, 1635, 10.1084/jem.20050807 · DOI
  33. Ma, 2002, The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations, Blood, 99, 1741, 10.1182/blood.V99.5.1741 · DOI
  34. Akin, 2003, Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit, Exp Hematol, 31, 686, 10.1016/S0301-472X(03)00112-7 · DOI
  35. Akin, 2004, A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib, Blood, 103, 3222, 10.1182/blood-2003-11-3816 · DOI · Paper page
  36. Zhang, 2006, A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy, Leuk Res, 30, 373, 10.1016/j.leukres.2005.08.015 · DOI · Paper page
  37. Alvarez-Twose, 2012, Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis, J Clin Oncol, 30, e126, 10.1200/JCO.2011.38.9973 · DOI
  38. de Melo Campos, 2014, Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412, Leuk Res, 38, 1245, 10.1016/j.leukres.2014.07.010 · DOI
  39. Harir, 2008, Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade, Blood, 112, 2463, 10.1182/blood-2007-09-115477 · DOI
  40. Blatt, 2012, The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils, PLoS One, 7, e29925, 10.1371/journal.pone.0029925 · DOI
  41. Gabillot-Carré, 2006, Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells, Blood, 108, 1065, 10.1182/blood-2005-06-2433 · DOI
  42. Baumgartner, 2009, Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V, Am J Pathol, 175, 2416, 10.2353/ajpath.2009.080953 · DOI
  43. Voisset, 2007, The tyrosine kinase FES is an essential effector of KITD816V proliferation signal, Blood, 110, 2593, 10.1182/blood-2007-02-076471 · DOI
  44. Parikh, 2010, Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis, Leuk Lymphoma, 51, 269, 10.3109/10428190903486220 · DOI
  45. Traina, 2012, Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis, PLoS One, 7, e43090, 10.1371/journal.pone.0043090 · DOI
  46. Wilson, 2011, Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis, Haematologica, 96, 459, 10.3324/haematol.2010.031690 · DOI
  47. Schwaab, 2013, Comprehensive mutational profiling in advanced systemic mastocytosis, Blood, 122, 2460, 10.1182/blood-2013-04-496448 · DOI
  48. Damaj, 2014, ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases, PLoS One, 9, e85362, 10.1371/journal.pone.0085362 · DOI
  49. Gleixner, 2011, KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib, Blood, 118, 1885, 10.1182/blood-2010-06-289959 · DOI
  50. Sotlar, 2008, Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a clonal hematological non-mast cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F, J Mol Diagn, 10, 58, 10.2353/jmoldx.2008.070061 · DOI
  51. Broesby-Olsen, 2012, Adult-onset systemic mastocytosis in monozygotic twins with KIT D816V and JAK2 V617F mutations, J Allergy Clin Immunol, 130, 806, 10.1016/j.jaci.2012.04.013 · DOI
  52. Ghanim, 2012, 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand, Blood, 119, 4242, 10.1182/blood-2011-09-382770 · DOI
  53. Wedeh, 2015, Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia, Leukemia, 29, 2230, 10.1038/leu.2015.138 · DOI
  54. Aichberger, 2007, Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412, Blood, 109, 3031, 10.1182/blood-2006-07-032714 · DOI
  55. Fumo, 2004, 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells, Blood, 103, 1078, 10.1182/blood-2003-07-2477 · DOI
  56. Kondo, 2007, Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells, Blood, 110, 661, 10.1182/blood-2006-10-054411 · DOI
  57. Santos, 2006, CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom’s macroglobulinemia and mast cell disorders, Clin Lymphoma Myeloma, 6, 478, 10.3816/CLM.2006.n.029 · DOI
  58. Krauth, 2007, Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils, Exp Hematol, 35, 108, 10.1016/j.exphem.2006.09.008 · DOI
  59. Sotlar, 2011, Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis, Mod Pathol, 24, 585, 10.1038/modpathol.2010.224 · DOI
  60. Morgado, 2013, CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis, Histopathology, 63, 780, 10.1111/his.12221 · DOI
  61. Hoermann, 2014, CD52 is a molecular target in advanced systemic mastocytosis, FASEB J, 28, 3540, 10.1096/fj.14-250894 · DOI
  62. Blatt, 2015, Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis, Blood, 126, 2832, 10.1182/blood-2015-03-637728 · DOI
  63. Pardanani, 2015, Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells, Leukemia, 29, 1605, 10.1038/leu.2015.16 · DOI
  64. Jeong, 2007, Successful treatment of systemic mastocytosis associated with AML-M2, t(8:21) in a child using MRC-based AML chemotherapy along with gemtuzumab, J Allergy Clin Immunol, 119, 207
  65. Alvarez-Twose, 2016, Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia, Leukemia, 30, 1753, 10.1038/leu.2016.30 · DOI
  66. Rabenhorst, 2016, Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severity, J Allergy Clin Immunol, 137, 314, 10.1016/j.jaci.2015.07.006 · DOI
  67. Valent, 2011, Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept, Curr Cancer Drug Targets, 11, 56, 10.2174/156800911793743655 · DOI
  68. Pelosi, 2015, Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells, Blood Cells Mol Dis, 55, 336, 10.1016/j.bcmd.2015.07.015 · DOI
  69. Eisenwort, 2014, Identification of a neoplastic stem cell in human mast cell leukemia, Blood, 124, 817, 10.1182/blood.V124.21.817.817 · DOI
  70. Kluin-Nelemans, 1992, Response to interferon alfa-2b in a patient with systemic mastocytosis, N Engl J Med, 326, 619, 10.1056/NEJM199202273260907 · DOI
  71. Casassus, 2002, Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients, Br J Haematol, 119, 1090, 10.1046/j.1365-2141.2002.03944.x · DOI
  72. Lim, 2009, Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine, Am J Hematol, 84, 790, 10.1002/ajh.21561 · DOI
  73. Kluin-Nelemans, 2003, Cladribine therapy for systemic mastocytosis, Blood, 102, 4270, 10.1182/blood-2003-05-1699 · DOI
  74. Barete, 2015, Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis, Blood, 126, 1009, 10.1182/blood-2014-12-614743 · DOI
  75. Ustun, 2014, Hematopoietic stem-cell transplantation for advanced systemic mastocytosis, J Clin Oncol, 32, 3264, 10.1200/JCO.2014.55.2018 · DOI
  76. Ustun, 2016, Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis, Biol Blood Marrow Transplant, 22, 1348, 10.1016/j.bbmt.2016.04.018 · DOI
  77. Fabbro, 2000, PKC412--a protein kinase inhibitor with a broad therapeutic potential, Anticancer Drug Des, 15, 17
  78. Ustun, 2011, Tyrosine kinase inhibitors in the treatment of systemic mastocytosis, Leuk Res, 35, 1143, 10.1016/j.leukres.2011.05.006 · DOI
  79. Growney, 2005, Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412, Blood, 106, 721, 10.1182/blood-2004-12-4617 · DOI
  80. Gleixner, 2006, PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects, Blood, 107, 752, 10.1182/blood-2005-07-3022 · DOI
  81. Gotlib, 2005, Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation, Blood, 106, 2865, 10.1182/blood-2005-04-1568 · DOI
  82. Krauth, 2009, Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells, Clin Exp Allergy, 39, 1711, 10.1111/j.1365-2222.2009.03353.x · DOI
  83. Gotlib, 2016, Efficacy and safety of midostaurin in advancedsystemic mastocytosis, N Engl J Med, 374, 2530, 10.1056/NEJMoa1513098 · DOI
  84. Chandesris, 2016, Midostaurin in advanced systemic mastocytosis, N Engl J Med, 374, 2605, 10.1056/NEJMc1515403 · DOI
  85. Gotlib, 2013, Durable responses and improved quality of life with midostaurin (PKC412) in advanced systemic mastocytosis (SM): updated stage 1 results of the global D2201 trial, Blood, 122, 106, 10.1182/blood.V122.21.106.106 · DOI
  86. Vega-Ruiz, 2009, Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis, Leuk Res, 33, 1481, 10.1016/j.leukres.2008.12.020 · DOI
  87. Paul, 2010, Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study, Am J Hematol, 85, 921, 10.1002/ajh.21894 · DOI
  88. Hochhaus, 2015, Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study, J Cancer Res Clin Oncol, 141, 2047, 10.1007/s00432-015-1988-0 · DOI
  89. Alvarez-Twose, Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature [published online ahead of print 19 July 2016], Oncotarget
  90. Pardanani, 2013, How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage), Blood, 121, 3085, 10.1182/blood-2013-01-453183 · DOI · Paper page
  91. Arock, 2015, Current treatment options in patients with mastocytosis: status in 2015 and future perspectives, Eur J Haematol, 94, 474, 10.1111/ejh.12544 · DOI
  92. Valent, 2010, How I treat patients with advanced systemic mastocytosis, Blood, 116, 5812, 10.1182/blood-2010-08-292144 · DOI
  93. Wimazal, 2012, Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience, Int Arch Allergy Immunol, 157, 399, 10.1159/000329218 · DOI
  94. Valent, 2003, Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria, Leuk Res, 27, 635, 10.1016/S0145-2126(02)00168-6 · DOI
  95. Gotlib, 2013, International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis, Blood, 121, 2393, 10.1182/blood-2012-09-458521 · DOI

Cited by

Sorted by citations

See all 592

Metadata

Authors
Valent, P., Akin, C., & Metcalfe, D. D.
Affiliations
  • Division of Hematology & Hemostaseology and Ludwig Boltzmann Cluster Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria;
  • Division of Allergy and Immunology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; and
  • Mast Cell Biology Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
ORCID
Venue
Blood
Publisher
American Society of Hematology
Published
2017-03-16
Volume
129
Issue
11
Pages
1420-1427
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2016-09-731893
Cited by
592
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review